Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Gsk Plc ADR (GSK)

Gsk Plc ADR (GSK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 88,204,832
  • Shares Outstanding, K 2,072,482
  • Annual Sales, $ 37,725 M
  • Annual Income, $ 6,130 M
  • 60-Month Beta 0.66
  • Price/Sales 2.39
  • Price/Cash Flow 8.30
  • Price/Book 5.13
Trade GSK with:

Options Overview Details

View History
  • Implied Volatility 20.76% ( -1.94%)
  • Historical Volatility 20.28%
  • IV Percentile 53%
  • IV Rank 50.02%
  • IV High 36.86% on 07/24/24
  • IV Low 4.64% on 08/29/24
  • Put/Call Vol Ratio 0.53
  • Today's Volume 528
  • Volume Avg (30-Day) 3,256
  • Put/Call OI Ratio 0.60
  • Today's Open Interest 92,554
  • Open Int (30-Day) 81,518

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 14 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/24
See More
  • Average Estimate 1.22
  • Number of Estimates 4
  • High Estimate 1.31
  • Low Estimate 1.14
  • Prior Year 1.26
  • Growth Rate Est. (year over year) -3.17%

Price Performance

See More
Period Period Low Period High Performance
1-Month
41.28 +2.79%
on 08/19/24
44.67 -5.01%
on 08/27/24
+1.15 (+2.79%)
since 08/16/24
3-Month
37.81 +12.23%
on 07/02/24
44.67 -5.01%
on 08/27/24
+1.48 (+3.61%)
since 06/18/24
52-Week
33.67 +26.00%
on 11/02/23
45.92 -7.61%
on 05/15/24
+5.08 (+13.60%)
since 09/18/23

Most Recent Stories

More News
AZN Gets FDA Nod for Fasenra Label Expansion in Rare Disease

AstraZeneca AZN announced that the FDA has approved its marketed asthma drug, Fasenra (benralizumab) for a new indication. The regulatory body has now approved Fasenra for treating adult patients with...

REGN : 1,138.81 (-0.69%)
SNY : 57.47 (+0.98%)
AZN : 78.58 (+0.06%)
GSK : 42.43 (-0.31%)
MRNA Stock Falls 12% on Lowered Sales Outlook, R&D Budget Cuts

At its annual R&D Day, Moderna MRNA announcedseveral updates about the advancements in its pipeline and its business outlook for the next four years.MRNA to Cut R&D Costs, Stops Five Pipeline ProgramsManagement...

SNY : 57.47 (+0.98%)
GSK : 42.43 (-0.31%)
MRK : 118.64 (+0.30%)
MRNA : 69.86 (-2.96%)
GSK's Respiratory Drug Nucala Meets Goal in COPD Study

GSK’s GSK phase III study evaluating its blockbuster drug Nucala (mepolizumab), an anti-IL5 biologic, for treating chronic obstructive pulmonary disease (COPD), met its primary endpoint.Data from the...

REGN : 1,138.81 (-0.69%)
SNY : 57.47 (+0.98%)
AZN : 78.58 (+0.06%)
GSK : 42.43 (-0.31%)
You Can Stop Looking, Here's the Perfect Stock for the Current Market

While technology stocks continue to struggle, stocks in the lucrative over-the-counter healthcare products sector are thriving. One prominent such name is Haleon. Its stock has jumped more than 22% over...

GSK : 42.43 (-0.31%)
HLN : 10.55 (-0.94%)
PFE : 29.75 (-0.27%)
JNJ : 166.15 (-0.55%)
KVUE : 23.19 (-0.86%)
SNY : 57.47 (+0.98%)
Vaxcyte Stock Hits Record High on Pneumococcal Vaccine Study Results

Shares of Vaxcyte PCVX rose more than 36% on Tuesday after it reported positive top-line results from a phase I/II study on VAX-31, which is an investigational 31-valent pneumococcal conjugate vaccine...

GSK : 42.43 (-0.31%)
PFE : 29.75 (-0.27%)
MRK : 118.64 (+0.30%)
PCVX : 116.54 (-0.18%)
GSK's RSV Vaccine Arexvy Gets EU Nod for Adults Aged 50-59 Years

GSK plc GSK has announced the approval of the European Commission (EC) for the expanded use of its respiratory syncytial virus (RSV) vaccine, Arexvy, in adults aged 50-59 years. The vaccine has been approved...

GSK : 42.43 (-0.31%)
PFE : 29.75 (-0.27%)
ILMN : 130.97 (+0.58%)
MRNA : 69.86 (-2.96%)
GSK Stock Gains 18.5% Year to Date: Time to Buy, Sell or Hold?

GSK GSK  stock has risen 18.5% so far this year compared with an increase of 27.1% for the industry. The stock has also been consistently trading above its 50-day and 200-day moving averages since mid-August.GSK...

GSK : 42.43 (-0.31%)
NVO : 132.06 (+0.05%)
LLY : 904.97 (-0.13%)
HLN : 10.55 (-0.94%)
Ozempic Medicare Negotiations Target Big Pharma in 2027

The anticipated 2027 Medicare drug negotiations are expected to impact several blockbuster drugs, with Novo Nordisk’s (NOVO) Ozempic, Pfizer’s (PFE) Ibrance and Xtandi, and GSK’s (GSK) Trelegy Ellipta...

PFE : 29.75 (-0.27%)
GSK : 42.43 (-0.31%)
TEVA : 17.88 (+0.17%)
ABBV : 192.94 (-0.26%)
Annovis Bio (NYSE: ANVS) Releases Promising Clinical Data As Alzheimer’s Therapeutics Market Grows

Annovis Bio (NYSE: ANVS), a late-stage, clinical-drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s disease (“AD”) and Parkinson’s disease...

ANVS : 8.36 (-4.35%)
PFE : 29.75 (-0.27%)
LLY : 904.97 (-0.13%)
GSK : 42.43 (-0.31%)
NVO : 132.06 (+0.05%)
Lucrative Incentive for Biotechs as Global Alzheimer's Disease Therapeutics Market Forecasted to Reach $30.8 Billion By 2033   

ANVS : 8.36 (-4.35%)
LLY : 904.97 (-0.13%)
GSK : 42.43 (-0.31%)
NVO : 132.06 (+0.05%)
PFE : 29.75 (-0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Weakening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

GSK plc is a biopharma company. Its vaccine portfolio protects people from meningitis, shingles, flu, polio, measles and many more. GSK plc, formerly known as GLAXOSMITHKLINE, is based in Brentford, the United Kingdom.

See More

Key Turning Points

3rd Resistance Point 43.28
2nd Resistance Point 43.09
1st Resistance Point 42.76
Last Price 42.43
1st Support Level 42.24
2nd Support Level 42.05
3rd Support Level 41.72

See More

52-Week High 45.92
Last Price 42.43
Fibonacci 61.8% 41.25
Fibonacci 50% 39.80
Fibonacci 38.2% 38.35
52-Week Low 33.67

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar